Ontario – Through Your Health: A Plan for Connected and Convenient Care, the Ontario government is providing people with the tools they need to stay safe and healthy throughout respiratory illness season. The risk of severe outcomes from RSV infection is highest among those over the age of 60, infants under six months of age and children under 24 months of age …
TORONTO — The Ontario government is expanding the Respiratory Syncytial Virus (RSV) program to connect more infants, high-risk children and pregnant women to RSV vaccines that can help protect themselves and their loved ones during the fall respiratory illness season. “Our government is taking steps to ensure Ontarians of all ages have the tools they need to be prepared and …
London – AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.1 Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season. Beyfortus is the first approved preventive option to protect against RSV in a …
